Lazarus CDS leverages Artificial Intelligence to improve early cancer detection by turning a primary care doctor into a specialist for 5 minutes. For diseases like cervical cancer, this is as simple as a simple prompt that alerts physicians of high-risk patients, enabling them to make better clinical decisions. In skin cancer, we turn any mobile device into an AI-powered dermascope, automatically classifying risk based on a whole host of factors. Best of all, it's fully explainable. No black boxes, just real results.

Lazarus uses patient health data and AI to detect cancer early. The company has clinical decision support systems for skin and cervical cancer, which help improve the diagnostic accuracy of physicians.

EyeArt is the first and only FDA-cleared AI technology for autonomous detection of both more than mild and vision-threatening diabetic retinopathy. The EyeArt® AI Eye Screening System is the most extensively validated autonomous AI technology, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.It is proven to be safe, fast, and consistent.